Clinical photodynamic therapy for superficial cancer in the esophagus and the bronchi: 514 nm compared with 630 nm light irradiation after sensitization with Photofrin II
Related publications (95)
Graph Chatbot
Chat with Graph Search
Ask any question about EPFL courses, lectures, exercises, research, news, etc. or try the example questions below.
DISCLAIMER: The Graph Chatbot is not programmed to provide explicit or categorical answers to your questions. Rather, it transforms your questions into API requests that are distributed across the various IT services officially administered by EPFL. Its purpose is solely to collect and recommend relevant references to content that you can explore to help you answer your questions.
New results are presented on the pharmacokinetics of the fluorescing fraction of Photofrin II in patients with an early cancer in the oesophagus or the buccal cavity. The light-induced fluorescence signal shows a relatively high contrast between tumor and ...
A rare EcoRI restriction fragment length polymorphism (RFLP) in the 3' end of the human c-mos locus has been identified in DNA from patients with breast tumors, esophageal carcinomas and leukemias. Until now, this RFLP has not been found in normal populati ...
The efficacy of photodynamic therapy (PDT) alone was evaluated on 41 ‘early’ squamous cell carcinomas of the pharynx (10), oesophagus (15) and tracheo-bronchial tree (16). All lesions but two were synchronous second primaries in ENT-patients suffering from ...
The timing has been optimized of photodetection (and possibly also phototherapy) of early cancer in the upper aerodigestive tract and bronchi and the relative concn. of fluorescent components of Photofrin II measured in patients as a function of the time a ...